Watson Kaitlyn E, Chan Jonathan C H, Pan Bo, Al Hamarneh Yazid N, Tsuyuki Ross T
EPICORE Centre, Department of Medicine, University of Alberta, Edmonton, Alberta.
Department of Pharmacology, University of Alberta, Edmonton, Alberta.
Can Pharm J (Ott). 2024 May 31;157(4):190-199. doi: 10.1177/17151635241254089. eCollection 2024 Jul-Aug.
We designed an online educational program for primary care health care providers, the Hypertension Canada Professional Certification Program (HC-PCP), based upon its 2020 guidelines.
The objective was to determine the effect of the HC-PCP, taken by pharmacists, on systolic blood pressure (BP) in patients with poorly controlled hypertension.
Stepped wedge cluster randomized trial (unit of randomization was the pharmacy).
Patients with poorly controlled hypertension (BP >140/90 mmHg or >130/80 mmHg [diabetes]) in community pharmacies in Alberta, Canada, were recruited by their pharmacist.
Pharmacists completed the HC-PCP program, then provided care to their patients with poorly controlled hypertension according to what they learned in the course.
Pharmacists were given a copy of the Hypertension Canada guidelines and provided their usual care to their patients prior to undertaking the HC-PCP later.
The primary outcome was a difference in change in systolic BP at 3 months between groups, while the secondary outcome was patient satisfaction with using the Consultation Satisfaction Questionnaire.
We enrolled 890 patients from 59 pharmacies (including 104 pharmacists). Using a linear mixed-effect model with BP reduction as the dependent variable and independent variables of treatment allocation, baseline BP, site effect and patient effect, the intervention was associated with a 4.76 mmHg (95% confidence interval, 2.02-7.50, < 0.0001) systolic BP reduction at 3 months. Patient satisfaction with using the Consultation Satisfaction Questionnaire was high at 75.9 (/90).
Most educational programs are not evaluated at the patient care level. The HC-PCP taken by pharmacists resulted in a 4.76 mmHg systolic BP reduction in their patients over 3 months. This would have major implications for public health, reducing heart disease, stroke and kidney failure.
我们基于2020年指南为初级保健医疗服务提供者设计了一个在线教育项目,即加拿大高血压专业认证项目(HC - PCP)。
目的是确定药剂师参与的HC - PCP对血压控制不佳的高血压患者收缩压的影响。
阶梯式楔形整群随机试验(随机单位为药房)。
加拿大艾伯塔省社区药房中血压控制不佳的高血压患者(血压>140/90 mmHg或糖尿病患者血压>130/80 mmHg)由其药剂师招募。
药剂师完成HC - PCP项目,然后根据他们在课程中学到的知识为血压控制不佳的患者提供护理。
在稍后进行HC - PCP之前,给药剂师一份加拿大高血压指南副本,并让他们为患者提供常规护理。
主要结局是两组在3个月时收缩压变化的差异,次要结局是使用咨询满意度问卷的患者满意度。
我们从59家药房招募了890名患者(包括104名药剂师)。使用以血压降低为因变量、治疗分配、基线血压、地点效应和患者效应为自变量的线性混合效应模型,干预措施与3个月时收缩压降低4.76 mmHg(95%置信区间,2.02 - 7.50,<0.0001)相关。使用咨询满意度问卷的患者满意度较高,为75.9(/90)。
大多数教育项目未在患者护理层面进行评估。药剂师参与的HC - PCP使患者在3个月内收缩压降低了4.76 mmHg。这将对公共卫生产生重大影响,减少心脏病、中风和肾衰竭。